These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 24423116)

  • 41. Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.
    Hanley PJ; Cruz CR; Shpall EJ; Bollard CM
    Cytotherapy; 2010 Oct; 12(6):713-20. PubMed ID: 20818913
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mouse model for pre-clinical study of human cancer immunotherapy.
    Ya Z; Hailemichael Y; Overwijk W; Restifo NP
    Curr Protoc Immunol; 2015 Feb; 108():20.1.1-20.1.43. PubMed ID: 25640991
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity.
    Stone JD; Harris DT; Kranz DM
    Curr Opin Immunol; 2015 Apr; 33():16-22. PubMed ID: 25618219
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Life or death of T cells with antigen-specific receptors--using T cells for cancer adoptive immunotherapy/gene therapy.
    Ren-Heidenreich L; Lum LG
    Curr Gene Ther; 2001 Sep; 1(3):253-5. PubMed ID: 12109140
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The potential and promise for clinical application of adoptive T cell therapy in cancer.
    Li Y; Zheng Y; Liu T; Liao C; Shen G; He Z
    J Transl Med; 2024 May; 22(1):413. PubMed ID: 38693513
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens.
    Jæhger DE; Hübbe ML; Kræmer MK; Clergeaud G; Olsen AV; Stavnsbjerg C; Wiinholt MN; Kjær A; Henriksen JR; Hansen AE; Andresen TL
    Sci Rep; 2021 Oct; 11(1):19794. PubMed ID: 34611284
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antigen choice in adoptive T-cell therapy of cancer.
    Offringa R
    Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.
    Fraietta JA; Schwab RD; Maus MV
    Semin Oncol; 2016 Apr; 43(2):291-9. PubMed ID: 27040708
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Application of T cell immunotherapy for human viral and malignant diseases.
    Riddell SR; Warren EH; Lewinsohn D; Mutimer H; Topp M; Cooper L; de Fries R; Greenberg PD
    Ernst Schering Res Found Workshop; 2000; (30):53-73. PubMed ID: 10943316
    [No Abstract]   [Full Text] [Related]  

  • 51. Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8
    Hasan AN; Selvakumar A; Shabrova E; Liu XR; Afridi F; Heller G; Riviere I; Sadelain M; Dupont B; O'Reilly RJ
    Clin Exp Immunol; 2016 Nov; 186(2):249-265. PubMed ID: 27227483
    [TBL] [Abstract][Full Text] [Related]  

  • 52. T cell receptor gene therapy for cancer.
    Schmitt TM; Ragnarsson GB; Greenberg PD
    Hum Gene Ther; 2009 Nov; 20(11):1240-8. PubMed ID: 19702439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity.
    Kebriaei P; Kelly SS; Manuri P; Jena B; Jackson R; Shpall E; Champlin R; Cooper LJ
    Front Biosci (Schol Ed); 2012 Jan; 4(2):520-31. PubMed ID: 22202074
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?
    Klebanoff CA; Gattinoni L; Restifo NP
    J Immunother; 2012; 35(9):651-60. PubMed ID: 23090074
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.
    Cieri N; Mastaglio S; Oliveira G; Casucci M; Bondanza A; Bonini C
    Immunol Rev; 2014 Jan; 257(1):165-80. PubMed ID: 24329796
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
    Srivastava S; Riddell SR
    J Immunol; 2018 Jan; 200(2):459-468. PubMed ID: 29311388
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
    Ott PA; Dotti G; Yee C; Goff SL
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.
    Sengupta S; Mao G; Gokaslan ZS; Sampath P
    Cancer Gene Ther; 2017 Mar; 24(3):121-129. PubMed ID: 27767090
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.
    Knochelmann HM; Smith AS; Dwyer CJ; Wyatt MM; Mehrotra S; Paulos CM
    Front Immunol; 2018; 9():1740. PubMed ID: 30140266
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cancer immunotherapy using tumor antigen-reactive T cells.
    Choi BK; Kim SH; Kim YH; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):235-245. PubMed ID: 29370726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.